ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 1715

Spondyloarthritis and Psoriatic Arthritis Patients Under Immunosuppressive Conventional and Biologic DMARDs: Favorable Disease Safety and Attenuated Immunogenicity Following Recombinant Herpes Zoster Vaccination
Abstract Number: 1716

The frequency and impact of cardiovascular disease in systemic lupus erythematosus: a Nationwide, matched case-control study.
Abstract Number: 1717

The Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI) Predicts Mortality In Systemic Lupus Erythematosus (SLE) Patients: Data From The Almenara Lupus Cohort
Abstract Number: 1718

Mortality and Hematological Adverse Events in Patients with Cancer Receiving Immune Checkpoint Inhibitors: Impact of Pre-existing Systemic Lupus Erythematosus
Abstract Number: 1719

Impact of SGLT2 Inhibitors on Cardiovascular Events, Mortality, and Lupus Nephritis in Patients with Systemic Lupus Erythematosus and Diabetes: Retrospective Cohort Study
Abstract Number: 1720

Comparison of Mortality Trends in Adults with Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus: A 21-Year Analysis Using CDC WONDER DATABASE.
Abstract Number: 1721

Excess Mortality in SLE Is Concentrated in Lupus Nephritis and aPL-Positive Subsets: A population-based inception cohort study
Abstract Number: 1722

Defining Safe Hydroxychloroquine Blood Levels: Time to Switch to Precision Monitoring for Optimized Lupus Care
Abstract Number: 1723

Impaired Maintenance of X-Chromosome Inactivation in B Cells, But Not T Cells, Exacerbates Interferon-Driven Systemic Autoimmunity
Abstract Number: 1724

Pathogenic role of Mucosal-Associated Invariant T cells in Rheumatoid Arthritis.
Abstract Number: 1725

Functional NOTCH4 Variants Drive Vasculopathy and Fibrosis in Systemic Sclerosis.
Abstract Number: 1726

Inflammatory arthritis immune related adverse events represent a unique autoimmune disease entity primarily driven by T cells, but likely not autoantibodies
Abstract Number: 1727

Distribution of Fracture Risk Status and Osteoporosis Treatment Use Among Postmenopausal Women with Osteoporosis in the United States
Abstract Number: 1728

Longitudinal Proteomic Signatures for Prediction of Immune-Related Adverse Events during Immune Checkpoint Inhibitors therapy: A Machine Learning-Guided Prospective Biomarker Discovery Study
Abstract Number: 1729

The ERIN Registry: Real-World Data on Rheumatic Immune-Related Adverse Events from Immune Checkpoint Inhibitor Therapy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].